Cervarix Group vs Placebo Group: Number of Subjects With Serious Adverse Events (SAEs)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.0185	0.0143	0.024	wilson	ClinicalTrials.gov
Risk in group 2	0.0268	0.0216	0.0332	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	-0.00827	-0.0159	-0.000753	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	0.691	0.493	0.968	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	0.685	0.486	0.967	log	ClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Cervarix Group than on Placebo Group	121	62.8	1,330	from the risk difference interval	ClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	Cervarix Group	Subjects received 3 doses of Cervarix vaccine. Cervarix vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.	56	3,026	OG000	ClinicalTrials.gov
Group 2	Placebo Group	Subjects received 3 doses of placebo. Placebo was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.	81	3,025	OG001	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	SECONDARY	ClinicalTrials.gov
Title	Number of Subjects With Serious Adverse Events (SAEs)	ClinicalTrials.gov
Description	SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.	ClinicalTrials.gov
Time frame	From Day 0 to Month 72	ClinicalTrials.gov
Population	The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.	ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects	ClinicalTrials.gov
NCT number	NCT00779766	ClinicalTrials.gov
Phases	PHASE3	ClinicalTrials.gov
Conditions	Infections, Papillomavirus	ClinicalTrials.gov
Interventions	HPV GSK 580299 vaccine, Placebo control	ClinicalTrials.gov
Lead sponsor	GlaxoSmithKline	ClinicalTrials.gov
Results first posted	2012-05-10	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT00779766?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.